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There are numerous evidences suggesting that inhibition of apoptosis of neurons
play a critical role in preventing the damage and even death of neurons after brain
ischemia/reperfusion, which shows therapeutic potential for clinical treatment of brain
injury induced by stroke. In this study, we aimed to investigate the neuroprotective effect
of Clematichinenoside (AR) and its underlying mechanisms. MCAOmode was performed
in rats and OGD/R model in primary cortical neurons to investigate the neuroprotective
effect of AR. The rate of apoptotic cells was measured using TUNEL assay in cerebral
cortex and flow cytometric assay in cortical neurons. Apoptosis-related proteins such as
bcl-2, bcl-xl, and bax and the phosphorylation of ERK1/2, cPKC, p90RSK, and CREB in
ischemic penumbra were assayed by western blot. Furthermore, we made a thorough
inquiry about how these proteins play roles in the anti-apoptotic mechanism using
targets-associated inhibitors step by step. The results revealed that AR could activate
both ERK1/2 and cPKC which resulted in p90RSK phosphorylation and translocation
into the nucleus. Moreover, CREB, a downstream target of p90RSK, was phosphorylated
and then bound to cAMP-regulated enhancer (CRE) to activate apoptosis-related genes,
and finally ameliorate ischemic stroke through preventing neuron death. In conclusion,
these data strongly suggest that AR could be used as an effective neuroprotective agent
to protect against ischemic stroke after cerebral I/R injury through regulating both ERK1/2
and cPKC mediated p90RSK/CREB apoptotic pathways.
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INTRODUCTION
Ischemic stroke which accounts for 85% of all stroke cases is associated with high morbidity and
mortality worldwide (Lu et al., 2012; Zhao et al., 2013). After cerebral ischemia and reperfusion
(I/R) injury, the cerebral microcirculatory damage, and apoptotic death of neurons have been found
to play a vital role in causing subsequent disability and mortality (Wang et al., 2014). Therefore,
agents that can prevent neuron death are believed to have therapeutic potentials toward brain I/R.
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ERK1/2 is an important subfamily of mitogen-activated
protein kinases that control a broad range of cellular activities
including cell survival and apoptosis, and it also plays
a critical role in triggering neuroprotective action toward
neurodegeneration diseases and stroke (Yoo et al., 2008; Zhang
et al., 2014; Wei et al., 2015). Further evidences provided that the
regulation of ERK1/2 was dependent on the activity of classical
or conventional PKC (cPKC) via the modulation of the kinase
Raf (Cheng et al., 2001). In addition, cPKC belongs to the PKCs
which can be categorized into conventional, novel and atypical
PKC (cPKC, nPKC, and aPKC) and has been implicated in cell
proliferation, differentiation, apoptosis, tumor promotion, and
neuronal activity (Ikenoue et al., 2008). In the present study, we
used ERK1/2 specific inhibitor PD98095 (Zanotto-Filho et al.,
2008) and cPKC broad band inhibitor GF109203X (Aaltonen
et al., 2007) to detect whether the neuroprotective effect of AR
was related to cPKC and ERK1/2 activation and how ERK1/2
and cPKC play roles in the process. Based on our results, we
demonstrated for the first time that the protective effects of AR
on OGD/R-induced apoptosis was not dependent on the classical
pathway cPKC/Raf/ERK1/2, but on both cPKC and ERK1/2
pathways.
Previous study revealed that p90RSK, activated by ERK1/2
in response to growth factors, was involved in regulation of
apoptotic cell death (Kim et al., 2008) and considered as a new
therapeutic approach for preventing brain injury (Koh, 2015).
Furthermore, Itoh et al. (2005) supported a new mechanism
that p90RSK, but not ERK1/2 activation, was increased in PKC
over-expressed mice. We inferred that cPKC and ERK1/2 could
regulate the common target-p90RSK respectively, and finally
showed stronger efficacy and downstream regulation than either
of them in our experiments. Additionally, CREB, a downstream
target of p90RSK, was activated by phosphorylation and then
subsequently regulated the expression of genes such as bcl-2, bcl-
xl, and bax in cellular physiological events including cell cycle
regulation, apoptosis etc (Hardingham et al., 2002; Kajimura
et al., 2014). Here, we used BI-D1870 as p90RSK specific inhibitor
(Sapkota et al., 2007) and KG-501 (Bell et al., 2013) as CREB
specific inhibitor to evaluate the action of p90RSK and CREB in
the apoptotic mechanism.
Plant-derived natural products play a crucial role in the field
of drug discovery. Clematischinensis Osbeck (Ranunculaceae;
in Chinese “Wei-Ling-Xian”), a common traditional Chinese
medicine, was used for treating patients who suffered from
myocardial infarction or ischemic stroke (Kuang et al., 2005).
Clematichinenoside (AR), a triterpene saponin isolated from the
root of Clematischinensis Osbeck, is a commonly used herb
with a long clinical practice history in Asia (Liu et al., 2009).
Previous studies exhibited that AR had some pharmacological
benefits, such as attenuating early-stage atherosclerosis by
inhibiting the expression of ICAM-1 and VCAM-1(Yan et al.,
2015), attenuating myocardial infarction by increasing SOD
activity, inhibiting excessive production of inducible nitric oxide
Abbreviations: AR, Clematichinenoside; CRE, cAMP-regulated enhancer; I/R,
cerebral ischemia and reperfusion; cPKC, classical or conventional PKC; MCAO,
middle cerebral artery occlusion.
synthase, and decreasing endothelial nitric oxide synthase (Zhang
et al., 2013). However, up to now, its effect on ischemic stroke
remains largely unknown. According to our pre-experiment,
we found that AR could prevent OGD/R-induced apoptosis in
primary cortical neurons. Hence, on the basis of this background,
the present study was designed: (1) to investigate the possible
neuroprotective effect of AR against ischemic stroke after
cerebral I/R injury in a rat MCAO model, (2) to determine
the molecular mechanism of anti-apoptotic effect of AR by
performing OGD/R model on rat cortical neurons, and (3) to
provide further information for future development of novel
neuroprotective agents.
Herein, we have not only determined the neuroprotective
effect of AR on ischemic stroke, but also made a strong
effort to reveal the underlying mechanism. Our results showed
that AR protected against ischemic stroke after cerebral I/R
injury through up-regulating the phosphorylation of ERK1/2
and cPKC, which mediated the enhanced p90RSK and CREB
phosphorylation. To further explore the mechanism, we
demonstrated that p90RSK could markedly transfer from
cytoplasm to nucleus after phosphorylation, and then promote
CREB phosphorylation and phospho-CREB binding to CRE,
which resulted in the alteration of bcl-2, bcl-xl, and bax
expressions in cortical neurons.
MATERIALS AND METHODS
Chemicals and Reagents
Clematichinenoside (95.3% purity) was provided by China
Pharmaceutical University. PD98095, GF109203X, BI-D1870,
and KG-501 were purchased from Shang Hai Haoran Biological
Technology CO., LTD (Shanghai, China) Dulbecco’s modified
Eagle’s medium (DMEM, high glucose) and newborn calf serum
were products of Gibco. Anti-ERK1/2, Anti-phospho-ERK1/2,
anti-PKCα, anti-PKCβI/βII, anti-PKCγ, anti-phospho-PKCα,
anti-phospho-PKCβI/βII, anti-phospho-PKCγ, anti-p90RSK,
anti-phospho-p90RSK, anti-CREB, anti-phospho-CREB, anti-
bcl-2, anti-bcl-xl, and anti-bax were purchased from Santa
Cruz Biotechnology, Inc. Primers for PCR were obtained from
Shanghai Sangon Biotech Co., Ltd. RT-PCR kit was bought from
Dalian Takara Biotechnology Co., Ltd.
Animal
Male Sprague-Dawley rats (220–250 g) were purchased from
Comparative Medicine Centre of Yangzhou University
(Yangzhou, China). Rats were kept under standard housing
conditions with a 12 h light/12 h dark cycle at 18–22◦C with free
access to food and water during the whole experiment procedure.
The animal study was performed strictly in accordance with
the National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Induction of Ischemia/Reperfusion Model
and AR Treatment
MCAO and reperfusion were served as ischemia/ reperfusion
(I/R) injury (Lv et al., 2011) andMCAOwas induced as described
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previously (Longa et al., 1989). Briefly, after anesthesia, the right
common carotid artery (CCA), external carotid artery (ECA),
and internal carotid artery (ICA) were exposed through a short
incision. CCA and ECA were ligated and ICA was temporarily
clamped by using artery clamp. A nylon monofilament was
inserted into the ICA via the ECA to block MCA. In the
sham group, rats received all the surgical procedures except the
filament inserted. Apart from sham group, all other groups were
experienced MACO surgery, and 24 h reperfusion was initiated
by withdrawing the filament after 2 h occlusion of MCA. After
reperfusion, rats were administrated intraperitoneally with AR
(8, 16, or 32mg/kg) or isopyknic physiological saline (vehicle) for
3 days, once per day.
Measurement of Cerebral Infarction Rate
and Cerebral Edema
At 72 h after reperfusion, animals were terminally anesthetized
and sacrificed by decapitation. The brains (n = 8) were
immediately removed and stored at −20◦C for 40min, and then
cut into five consecutive coronal slices with 2mm thickness
after removal of cerebellum. Brain slices were placed into 2%
TTC saline solution then incubated in a thermostatic water bath
at 37◦C for 30min. Slices treated with 4% paraformaldehyde
were refrigerated at 4◦C for 24 h in dark. After TTC staining,
the colored area and the non-colored area of the slices were
respectively measured by a blinded observer with Image J
software, and the area of ischemic brain injury was calculated and
expressed as infarct area percentage (%). To determine cerebral
edema, brains (n = 8) were quickly removed and weighed
(wet weight). Before weighed again (dry weight), brains were
dehydrated in 105◦C for 24 h. Cerebral edema (%) = (1–dry
weight/ wet weight)×100%.
Evaluation of Neurologic Deficits
At 72 h after reperfusion, the neurologic behavior assessment
was carried out by an investigator who was unaware of animal
grouping according to previous methods (Longa et al., 1989).
The neurologic findings were scored using a 5-point scale:
0, no neurologic deficit; 1, fail to extend forepaw fully; 2,
counterclockwise circling; 3, failure to the left or no autonomous
motor activity; and 4, fail to walk spontaneously and response to
external noxious stimulus.
Tissue Preparations
After rats were sacrificed, brain tissues were immediately
removed to 10% paraformaldehyde and embedded with
paraffin, and then rapidly frozen at −20◦C until use for
immunohistochemical analysis and TUNEL staining.
Immunohistochemistry and TUNEL
Staining
After rats were sacrificed, left cortical samples (n = 8)
were harvested under anesthesia and fixed in 10% neutral
buffered formalin, embedded in paraffin and sliced with a
cryostat into sections of 10-µm thickness for subsequent
immunohistochemistry and TUNEL staining. To perform
immunohistochemistry, sections were blocked by 8% normal
goat serum and then incubated with rat anti-bcl-2 antibody
(1:200), anti-bcl-xl antibody (1:200), or anti-bax antibody (1:200)
for 24 h at 4◦C. After being washed with PBS for three times,
sections were incubated with Alexa 488-conjugated secondary
antibodies for 30min at 37◦C.
TUNEL staining was performed according to previous
methods (Lee et al., 2014). Briefly, sections (n = 8) were
stained using terminal deoxynucleotidyl transferase-mediated
dUTP nick end labeling (TUNEL) reagents in situ Apoptosis
Detection Kit (Chemicon International, Inc., USA). Images were
obtained by fluorescence microscope (IX-71, Olympus, Tokyo,
Japan) with a digital camera (Olympus) and analyzed using
Image pro plus software (Media Cybernetics, Silver Spring, MD).
The number of TUNEL–positive cells was counted from three
random 1× 1mm2 areas.
Cell Culture, Oxygen Glucose
Deprivation/Reoxygenation (OGD/R) Injury
and Cell Viability Determination
The experiment was performed according to the previously
described method with a few modifications (Huang et al.,
2015). The primary cultures of cortical neurons were harvested
from E15-18 embryos of pregnant Spraguee-Dawley rats. Then
neurons were digested in 1000mL cysteine (0.25%), stopped by
adding 200mL fetal bovine serum (FBS) and gently resuspended
in MEM medium containing 10% (v/v) FBS, and dissociated
properly. After filtration, the cortical tissues were centrifuged at
1000 rpm for 5min, and then resuspended in MEM + 10% (v/v)
FBS. After the supernatant was discarded, cortical neuron cells
were plated at 1 × 106 g/ml onto 24 or 6 well culture plates pre-
coated with cell adhesion solution (0.5%; Applygen Technologies
Inc, Beijing, China). The culture plates were stored in a 5%
CO2 humidified incubator for 6 h at 37◦C (Thermo, Waltham,
MA, USA). Then, the culture media was replaced by Neurobasal
Media supplemented with 2% B27 (v/v). Neurons were routinely
cultured and maintained for 7–8 days for using in the following
experiments.
The OGD/Rmodel was carried out to mimic I/R injury in vivo
according to previously established method (Fan et al., 2014)
with a few modifications. After 7–8 days in culture, the cortical
neurons were refreshed with glucose-free DMEM medium and
placed in an anaerobic chamber fully flushed with 80% N2 and
20% CO2 (pH 6.8) to mimic the acidic environment of ischemic
brain in vivo at 37◦C for 2 h. Subsequent reoxygenation was
carried out by exposing neurons to normal medium and further
incubating for 24 h. After OGD/R induction, cortical neurons
were treated with or without AR (3, 10, and 30µM) in the
presence or absence of PD98095 (20µM, a specific ERK1/2
inhibitor) and/or GF109203X (5µM, a specific PKC inhibitor)
for indicated time in the following experiments. Cell viability was
evaluated by MTT assay as described previously (Fan et al., 2014)
at 8 h after incubation.
Apoptosis Detection and LDH Assay
After 8 h treatment with indicated agents, the treated cortical
neurons were digested with trypsin (2.5 g/l), centrifuged at
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1000 rpm for 10min and resuspended, and then loaded with
Annexin V-FITC/propidium iodide (PI) at 4◦C for 30min.
The apoptotic frequency was quantified by flow cytometry
with FACSCanto (Becton Dickinson) as previously described
(Naumann et al., 2009).
The cell injury was evaluated by measuring lactate
dehydrogenase (LDH). LDH release was detected in culture
medium using the LDH assay kit (Jiancheng, Nanjing, China)
according to previous research (Zhang et al., 2012). After
OGD/R and followed by 8 h treatment with indicated agents,
LDH release was measured at 492 nm using a microplate reader
(BioRad), while the background absorbance at 620 nm was
subtracted.
Western Blot Analysis
At 72 h after reperfusion, animals were executed under 10%
chloral hydrate anesthesia. The infarct side of cortex (from an
area between 3 and 6mm posterior to the frontal pole) was
harvested and stored at −80◦C until protein extraction. As for
in vitro study, neurons were washed twice with ice-cold PBS
and collected for subsequent protein extraction after treatment
with indicated agents at different indicated times. Protein
extracts from nuclear and cytosolic fraction were obtained using
a nuclear extraction kit following the manufacturer protocol
(Millipore, Bedford, MA, USA), while protein concentration
was determined by Bradford assay. Equal amounts of total
protein extracts or nuclear protein extracts were separated in
10% SDS-PAGE and transferred onto polyvinylidene difluoride
membranes. After being blocked with 5% nonfat milk in TBST
(0.1% Tween 20 in TBS) for 1 h at room temperature, the
membranes were incubated with primary antibodies overnight
at 4◦C. Then the membranes were incubated with HRP-
conjugated secondary antibodies at room temperature for 2 h.
Then the membrane was incubated with horseradish peroxidase-
conjugated secondary antibody for 2 h. Labeled proteins were
detected with the ChemiDocXRS+ chemiluminescence imaging
system (Bio-Rad, Hercules, CA, USA) and the intensity of
bands were quantified by Image pro plus software. The
bcl-2, bcl-xl, and bax expression levels were normalized to
β-actin, while the phosphorylated level was expressed as a
ratio of phosphorylated protein to total protein. In addition,
the cytoplasmic p90RSK level was normalized to cytoplasmic
β-actin, and the nuclear p90RSK level was normalized to nuclear
β-tubulin.
Quantitative Real-Time PCR
For preparation of total RNA of primary cortical neurons,
total RNA extraction reagent (Vazyme, Nanjing, China) was
applied as manufacturer’s instructions after 8 h treatment with
indicated agents. While cDNA preparation with Prime Script
RT reagent kit (Takara, Dalian, China) completed, quantitative
real-time PCR was carried out using SYBR Premix Ex Taq II
(Takara, Dalian, China) on 7500 Real-Time PCR System (Applied
Biosystems, CA, USA). Specific forward and reverse primers
were as follows: bcl-2, forward primers, 5′- GAACTGGGGGAG
GATTGTGG -3′, reverse primers, 5′- GCATGCTGGGGCCATA
TAGT -3′, 194 bps; bcl-xl, forward primers, 5′- AGGGGCTTA
GCTGCTGAAAG -3′, reverse primers, 5′- GTGGACAAGGAT
CTTGGGGG -3′, 81 bps; bax, forward primers, 5′- CTGGATC
CAAGACCAGGGTG -3′, reverse primers, 5′- GTGAGGACT
CCAGCCACAAA -3′, 96 bps. GAPDHmRNA acted as a control
to get the relative quantification.
Statistical Analysis
Apart from neurological deficit scores, other data were expressed
as means ± SD. Statistical analyses were carried out using
the SPSS 16.0 software, and the significance of intergroup
differences was compared using the One-way ANOVA followed
by Bonferroni post-hoc test. Probability value (P) less than 0.05
was considered to be statistically significant. The neurological
deficit scores were expressed as the median (range) and analyzed
with a Kruskal–Walls test followed by the Mann–WhitneyU-test
for multiple comparisons. All statistical figures were performed
with Graph Pad Prism Version 6.0.
RESULTS
AR Ameliorated Ischemia/Reperfusion
Lesion by Reducing Infarct Area, Cerebral
Edema, and Neurologic Deficits In vivo
Three-day intraperitoneal administration of AR notably
diminished infarct volumes of MACO rats. As illustrated in
Figures 1A,B, a remarkably decreased pale-colored region was
observed in AR (8, 16, and 32mg/kg) treated rats (p < 0.05,
p < 0.01, p < 0.001). Similarly, the ratio of cerebral edema
significantly decreased (p < 0.05, p < 0.01) in rats administrated
with AR (16 and 32mg/kg) at 72 h after reperfusion (Figure 1C).
Neurological behavioral tests also indicated that rats in AR-
treated groups (8, 16, and 32mg/kg) performed better on
the behavioral test and got lower neurological deficit scores
(p < 0.05, p < 0.01, p < 0.001; Figure 1D). These data were
sufficient to confirm that AR can serve as a feasible agent to
lessen ischemia/reperfusion injury in animal model.
AR Impeded Apoptosis via Modulating
bcl-2, bcl-xl, and bax Expressions in the
Cortex of MCAO Rats
To shed light on the mechanism of AR-induced outstanding
anti-cerebral ischemia action, TUNEL assay was performed.
The number of TUNEL-positive cells in the penumbral area
of MCAO rats (Figure 2B) was significantly reduced by AR
treatment (8, 16, and 32mg/kg) as compared with that in vehicle
group (p < 0.05, p < 0.01, p < 0.001; Figures 2A,C).
Furthermore, immunohistochemical staining indicated that a
dramatic increment of immunoreactive cells for bcl-2 (p < 0.05,
p < 0.01, p < 0.001) and bcl-xl (p < 0.05, p < 0.01, p <
0.001) was found in MCAO rats experiencing AR-treatment (8,
16, and 32mg/kg; Figures 2A,D,E), while the bax-positive cell
numbers in cortex appeared to be reduced in AR treated MCAO
rats (8, 16, and 32mg/kg; p < 0.05, p < 0.01, p < 0.001;
Figures 2A,F), suggesting that anti-apoptosis pathway seemed
to serve as a pivotal role in the anti-cerebral ischemia triggered
by AR.
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FIGURE 1 | The effect of AR on cerebral infarction, cerebral edema, and neurological deficit score in MCAO rats. The vehicle group and AR groups
underwent MCAO while the sham group underwent the same surgical procedure without the filament inserted. After MCAO performed, rats in AR groups were
intraperitoneally administrated with AR (8, 16, and 32mg/kg) for 3 days. (A) TTC staining was applied after rats were sacrificed, and brain images were analyzed by
Image J software. And infarct area percentage data indicated in (B) were calculated as infarct area/whole area. (C) Cerebral edema was calculated as formula
illustrated in the methods. (D) The neurological deficit evaluation were performed at 72 h after reperfusion and analyzed with a Kruskal–Walls test followed by the
Mann–Whitney U-test for multiple comparisons. Apart from neurological deficit scores, other data were presented as mean ± SD, neurological deficit scores were
presented as median (n = 8). *P < 0.05; **P < 0.01; ***P < 0.001. N.S, not significant.
AR Improved Primary Cortical Neurons
Survival and Mitigated Cell Apoptosis and
Injury Induced by OGD/R
As shown in Figure S1, the inhibitive effect of 20µM
PD98095 on ERK1/2 phosphorylation, and the inhibitive effect
of 5µM GF109203X on cPKC (PKCα, PKCβ1/β2, PKCγ)
phosphorylation could reach the maximum in primary cortical
neurons, so that the concentrations were used for the following
experiments. After 8 h AR or inhibitors treatment, primary
cortical neurons viability was determined by MTT assay. It was
found that while OGD/R caused neurons to incur great loss in cell
viability (p < 0.001), AR (3, 10, 30µM) remarkably abated this
decrement (p < 0.05, p < 0.01, p < 0.001). Interestingly, this
AR-triggered action was partly blocked by PD98095 (20µM) or
GF109203X (5µM; p < 0.05, p < 0.05), and was totally reversed
in the presence of PD98095 (20µM) and GF109203X (5µM;
Figure 3J). Additionally, Figure 3J also showed that PD98095
(20µM) or GF109203X had no toxic effects on cortical neurons.
Similarly, an obvious increment in apoptosis rate also appeared
after OGD/R (p < 0.001), and this augmented apoptosis rate
in neurons was markedly reduced by 8 h AR treatment (3, 10,
30µM; p < 0.05, p < 0.01, p < 0.001). Moreover, AR-induced
anti-apoptosis effect was canceled on condition that neurons
were incubated with both PD98095 (20µM) and GF109203X
(5µM) for 8 h together with AR incubation. But incubation with
PD98095 (20µM) or GF109203X (5µM) respectively failed to
indicate the same effect, and declined apoptosis rate in cortical
neurons caused by AR was slightly reversed in this condition
(p < 0.05, p < 0.05; Figures 3A–I). Measurement of LDH release
into the culture medium was carried out to assess cell injury
after 8 h incubation (Figure 3K). In response to OGD/R injury, a
notable elevation of LDH levels in culture medium was detected
(p < 0.001), while this change in LDH release was reversed by AR
(3, 10, 30µM; p < 0.05, p < 0.01, p < 0.001) in various degrees.
However, when this AR-induced protective action was challenged
by PD98095 (20µM) or GF109203X (5µM) respectively, its
inhibition on LDH release was partly canceled (p < 0.05,
p < 0.05). In the presence of these two specific inhibitors,
AR-treatment did not affect this augmented LDH release.
Upregulated ERK1/2 and cPKC
Phosphorylation Along with p90RSK
Translocation into Nucleus and CREB
Activation Mediated bcl-2, bcl-xl, and bax
Expressions in Response to AR
In view of the alterations of bcl-2, bcl-xl and bax expressions
in vivo, we then investigated other related proteins involved
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FIGURE 2 | The effect of AR on neurons apoptosis and bcl-2, bcl-xl, and bax expressions in the penumbral area. The vehicle group and AR groups
underwent MCAO while the sham group underwent the same surgical procedure without the filament inserted. After MCAO performed, rats in AR groups were
intraperitoneally administrated with AR (8, 16, and 32mg/kg) for 3 days. (A) Representative photographs of TUNEL staining, immunohistochemical staining of bcl-2,
bcl-xl, and bax in the cortex of MCAO rat. (B) The black square indicates the penumbral area. (C) TUNEL staining was analyzed by Image Pro Plus, and each datum
was presented as TUNEL positive cells numbers in per mm2 within five random independent view fields. Quantification of the levels of bcl-2 (D), bcl-xl (E), and bax
(F) expressions was presented as immunohistochemical positive cells numbers in per mm2 within five random independent view fields. The values were presented as
mean ± SD (n = 8). *P < 0.05; **P < 0.01; ***P < 0.001.
in this action. In this part, primary cortical neurons were
incubated with 10µM AR for indicated time after OGD/R,
and then the proteins derived from each sample were subjected
to western blot analysis. As shown in Figures 4A,B, after
AR incubation, obvious upregulations in phosphorylation rates
of ERK1/2 and PKCα, PKCβ1/β2, and PKCγ emerged, and
reached the maximum (62.5, 58.7, 51.9, and 56.2%) at 2 h,
then their phosphorylation rates began to decline till 6 h. As
phosphorylation and subsequent translocation of p90RSK are
upstream events of CREB activation that act as a crucial
role in modulating bcl-2 and bcl-xl expressions, time kinetics
of p90RSK phosphorylation and translocation were studied.
p90RSK phosphorylation initiated at 1 h after AR treatment and
with the maximum at 4 h, then reduced to a basal level at
about 10 h (Figures 4C,D). p90RSK translocation into nucleus
was almost synchronous with its phosphorylation process, the
maximum that p90RSK shuttled into nucleus from cytoplasm
appeared at 4 h after AR incubation, and this level maintained
at least 8 h afterwards (Figures 4E,F). As a positive transcription
modulator, CREB being phosphorylated by other kinase was
essential for its activation and followed by binding to CRE. At 2 h
after AR incubation, CREB phosphorylation started and reached
the extremum at 6 h, then returned to a basal level at about 12 h
(Figures 4G,H). In response to AR-triggered CREB activation,
bcl-2 and bcl-xl expressions were increased at about 4 h, while
bax expressions started to decline at same time, and reached
the extremum at 6 h after AR treatment, then the expressions
remained stable during the later 8 h (Figures 4I,J).
AR-induced p90RSK Phosphorylation and
Translocation Depended on both ERK1/2
and cPKC Activation
As shown in Figures 5A–E, the phosphorylation rates of
ERK1/2 and PKCα, PKCβ1/β2, and PKCγ were markedly
reduced in cortical neurons experiencing OGD/R, while AR
(3, 10, 30µM) treatment obviously restored this decreased
phosphorylation level (P < 0.05, P < 0.01, P < 0.001).
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FIGURE 3 | The effect of AR on apoptosis rates, cell viability, LDH levels in primary cortical neurons. After OGD/R and then followed by 8 h AR (3, 10, and
30µM) or indicated inhibitors treatment, the OGD/R was applied as illustrated in methods. Apoptosis rates were detected with annexin V/PI double staining after
incubation and presented in (A) normal neurons, (B) neurons only experiencing OGD/R, (C) neurons treated with 3µM AR after OGD/R, (D) neurons treated with
10µM AR after OGD/R, (E) neurons treated with 30µM AR after OGD/R, (F) neurons were exposed to PD98095 together with 10µM AR treatment 8 h after OGD/R,
(G) neurons were exposed to GF109203X together with 10µM AR treatment 8 h after OGD/R, and (H) neurons were exposed to PD98095 and GF109203X together
with 10µM AR treatment 8 h after OGD/R. (I) Quantification of apoptotic rates. (J) Cell viability was analyzed by MTT assay and data were described as % of normal
neurons. (K) Neurons injury was determined by LDH activity assay. Results mentioned-above were mean ± SD for 4 individual experiments which, for each condition,
were performed in quadruplicate. *P < 0.05; **P < 0.01; ***P < 0.001. N.S, no significant.
Additionally, the phosphorylation rates of ERK1/2 or cPKC
were inhibited by special inhibitor (PD98095 or GF109203X)
respectively. To investigate the relationship between p90RSK
translocation and ERK1/2 and cPKC phosphorylation, two
specific inhibitors targeting ERK1/2 and cPKC were applied.
After OGD/R injury, p90RSK phosphorylation levels were
diminished by ∼70% (P < 0.001), and AR (3, 10, 30µM)
incubation alleviated this lose in phosphorylation rates (P
< 0.05, P < 0.01, P < 0.001). However, when inhibitors
PD98095 (20µM) or GF109203X (5µM) were respectively
added to the medium together with AR (10µM) incubation
for indicated times, this increment of phosphorylation
rates triggered by AR (10µM) was slightly reduced (P <
0.05, P < 0.05). And when the two inhibitors were added
simultaneously, AR (10µM)-induced upregulation of p90RSK
phosphorylation was thoroughly abolished (Figures 5F,G).
Additionally, the phosphorylation rate of p90RSK was
inhibited by BI-D1870. This observation was in line with
p90RSK translocation process detected in our experiments.
OGD/R condition notably inhibited p90RSK translocation
into nucleus, while AR (3, 10, 30µM) restored this p90RSK
distribution between cytoplasm and nucleus by promoting
p90RSK shuttling into nucleus (P < 0.05, P < 0.01, P < 0.001;
Figures 5H–J).
CREB Activation was Essential for
Up/Down-Regulation of bcl-2, bcl-xl, and
bax Transcription and Expression in
Response to AR
In this part, BI-D1870 (specific inhibitor of p90RSK) and KG-
501 (specific inhibitor of CREB) were used to determine the role
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FIGURE 4 | The effect of AR on the phosphorylation of ERK1/2, cPKC, p90RSK, CREB and bcl-2, bcl-xl and bax expressions in primary cortical
neurons after OGD/R. Primary cortical neurons were treated with 10µM AR for indicated time after OGD/R operation and then protein phosphorylation levels or
expressions were determined by western blot assay. (A) Representative result of ERK1/2 and cPKC (PKCα, PKCβ1/β2, PKCγ) phosphorylation alterations in neurons
experiencing different time AR treatment, and data from four individual experiments were described in (B). (C) Representative results of p90RSK phosphorylation
alterations in neurons experiencing different time AR treatment, and this time-kinetic data were described in (D). (E) Representative result of p90RSK
nucleus-cytoplasm distribution alterations in neurons experiencing different time AR treatment, and this time-kinetic data were described in (F). (G) Representative
result of CREB phosphorylation alterations in neurons experiencing different time AR treatment, and this time-kinetic data were described in (H). (I) Representative
result of bcl-2, bcl-xl, and bax expressions changes in neurons experiencing different time AR treatment, and this time-kinetic data were described in (J). Results
mentioned-above were mean ± SD for four individual experiments which, for each condition, were performed in quadruplicate.
of p90RSK and CREB in the modulation of bcl-2, bcl-xl, and bax
expression in response to AR. As a result, a significant decline
of CREB phosphorylation level was observed in OGD/R treated
neurons (p < 0.001), and this decrease in CREB phosphorylation
was reversed by AR treatment (3, 10, 30µM) in various degrees
(p < 0.05, p < 0.01, p < 0.001). While this action of AR on
CREB phosphorylation was slightly blocked in the presence of
PD98095 (20µM; p < 0.05) or GF109203X (5µM; p < 0.05),
incubation with both PD98095 (20µM) and GF109203X (5µM)
or BI-D1870 (10µM) alone was sufficient to totally suppress this
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FIGURE 5 | AR-modulated p90RSK translocation depended on ERK1/2, cPKC (PKCα, PKCβ1/β2, PKCγ) phosphorylation. OGD/R were applied, and then
incubation with AR (10µM) or indicated inhibitors for indicated times. (A) Representative results of ERK1/2 and cPKC (PKCα, PKCβ1/β2, PKCγ) phosphorylation
alterations in neurons experiencing 2 h AR treatment or inhibitor(s) blocking after OGD/R, and quantification data from four individual experiments were described in
(B) ERK1/2, (C) PKCα, (D) PKCβ1/β2, and (E) PKCγ. (F) Representative result of p90RSK phosphorylation alterations in neurons experiencing 4 h AR treatment or
inhibitor(s) blocking after OGD/R, and this quantification data were described in (G). (H) Representative result of p90RSK nucleus-cytoplasm distribution alterations in
neurons experiencing 6 h AR treatment or inhibitor(s) blocking after OGD/R, and this quantification data were described in (I,J). Results mentioned-above were mean
± SD for four individual experiments which, for each condition, were performed in quadruplicate. *P < 0.05; **P < 0.01; ***P < 0.001.
up-regulation (p < 0.01, p < 0.01; Figures 6A,B). Additionally,
the phosphorylation rate of CREB was inhibited by KG-501. To
investigate bcl-2, bcl-xl, and bax mRNA and protein expressions,
qPCR and western blot analysis were applied (Figures 6C–I).
As a result, bcl-2 and bcl-xl mRNA or protein expressions were
up-regulated by AR (3, 10, 30µM) incubation after OGD/R,
while bax mRNA and protein levels in cortical neurons were
reduced by virtue of AR (3, 10, 30µM) after OGD/R. These AR-
induced alterations were partly reversed by PD98095 (20µM;
p < 0.05) or GF109203X (5µM; p < 0.05), and were almost
wholly blocked by combined incubation with PD98095 (20µM)
and GF109203X (5µM) or KG-501 (10µM) alone (p < 0.01,
p < 0.01).
AR Augmented the Phosphorylation Levels
of ERK1/2, cPKC, p90RSK, and CREB and
Mediated bcl-2, bcl-xl, and bax
Expressions In vivo
At 72 h after MCAO injury, ERK1/2, cPKC, p90RSK, and CREB
phosphorylation levels in the infarct side of cortex were markedly
reduced, which was in accordance with the results obtained
in vitro (Figures 7A–G). While AR (8, 16, and 32mg/kg) was
administrated intraperitoneally to rats after MACO/R surgery,
these decreased phosphorylation rates were up-regulated in
various degrees. The expressions of downstream proteins bcl-2,
bcl-xl, and bax were also detected after indicated treatment.
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FIGURE 6 | AR-mediated bcl-2, bcl-xl, and bax expressions depended on the activation of p90RSK and CREB. OGD/R were applied, and then incubation
with AR (3, 10, 30µM) or indicated inhibitors for indicated times. (A) Representative result of CREB phosphorylation alterations in neurons experiencing 6 h AR
treatment or inhibitor(s) blocking after OGD/R, and this quantification data were described in (B). (C) Representative results of bcl-2, bcl-xl, and bax expressions
changes in neurons experiencing 8 h AR treatment or inhibitor(s) blocking after OGD/R, and quantification data from four individual experiments were described in (D)
bcl-2, (E) bcl-xl, and (F) bax. Bcl-2 (G), bcl-xl (H), and bax (I) gene expressions changes in neurons experiencing 8 h AR treatment or inhibitor(s) blocking after OGD/R
were evaluated using qRT-PCR assay, and quantification data were from four individual experiments. Results mentioned-above were mean ± SD for four individual
experiments which, for each condition, were performed in quadruplicate. *P < 0.05; **P < 0.01; ***P < 0.001.
As a result, bcl-2 and bcl-xl levels in cortex were decreased
after MCAO and reperfusion, and bax levels were augmented in
MACO group as compared with sham group. These alterations
in protein expressions were almost reversed by AR treatment
(8mg/kg, 16mg/kg and 32mg/kg; Figures 7A,H–J).
DISCUSSION
Stroke, which is associated with high morbidity and mortality,
has become the third leading cause of death in many
countries (Lu et al., 2012; Zhao et al., 2013). Increased
mortality rate of neuronal cells following cerebral I/R is
a major cause for ischemic stroke (Kim et al., 2015).
Because of the increased risk, new agents for ischemic
stroke are urgently needed. Recently, a principal active
component, clematichinenoside (AR) was shown to possess anti-
inflammatory and antirheumatoid activities (Li et al., 2013). It has
been shown that AR was potentially beneficial for cardiovascular
diseases. Furthermore, our pre-test results showed that AR
prevented apoptosis induced by OGD/R injury in primary
cortical neurons.
In the present study, we performed both in vivo and in vitro
experiments to explore whether AR had the neuroprotective
effect on ischemia. Collectively, our results showed that
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 January 2016 | Volume 9 | Article 517
Liu et al. Clematichinenoside Ameliorates Ischemic Stroke
FIGURE 7 | The effect of AR on the phosphorylation of ERK1/2, cPKC, p90RSK, CREB and bcl-2, bcl-xl and bax expressions in cortex of MCAO rats.
The vehicle group and AR groups underwent MCAO while the sham group underwent the same surgical procedure without the filament inserted. After MCAO
performed, rats in AR groups were intraperitoneally administrated with AR (8, 16, and 32mg/kg) for 3 days. (A) Representative results of ERK1/2, cPKC, p90RSK,
CREB phosphorylation alterations and bcl-2, bcl-xl, and bax expressions changes in MCAO rats, and quantification data were described in (B) ERK1/2
phosphorylation level, (C) PKCα phosphorylation level, (D) PKCβ1/β2 phosphorylation level, (E) PKCγ phosphorylation level, (F) p90RSK phosphorylation level, (G)
CREB phosphorylation level, and (H) bcl-2, (I) bcl-xl, and (J) bax expressions. Results mentioned-above were described as mean ± SD (n = 8). *P < 0.05; **P < 0.01;
***P < 0.001.
administration of AR reduced the neurological deficit score
(Figure 1C), the brain edema (Figure 1D) and the elevated
infarct size in rat brain after injury (Figures 1A,B). Apoptosis
plays an important role in the process of cerebral I/R (Broughton
et al., 2009). Previous study revealed that apoptosis-associated
genes such as bcl-2, bcl-xl, and bax were activated by transient
cerebral ischemia. As the anti-apoptotic factors, bcl-2 and bcl-xl
were pivotal for cell survival while bax can promote apoptosis
(Yang et al., 1995; Koistinaho and Hokfelt, 1997). Further study
verified that AR could effectively reduce the apoptotic rate after
MCAO using TUNEL staining. To investigate the ability of AR
on preventing neuronal cell death after ischemia in vitro, we
performed the OGD/R model in cortical neurons. The LDH
activity was considered as an index of cell injury in the OGD/R
induced cortical neurons (Wu et al., 2014). The decreased LDH
activity induced by AR demonstrated that AR could markedly
attenuate the cell injury (Figure 3K). Furthermore, we used
flow cytometric analysis to test apoptosis in neuron cells which
was considered as a critical consequence of cerebral I/R injury
(Sun et al., 2010). As expected, the apoptotic rate in cortical
neuron cells was markedly reduced by AR (Figure 3I). Besides,
immunohistochemistry, western blot and qRT-PCR assays also
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confirmed the effects of AR on the expressions of bcl-2, bcl-xl,
and bax. Additionally, we noticed that PD98095, GF109203X,
and KG-501 significantly blocked the effect of AR on the
expressions of bcl-2 bcl-xl and bax, indicating that CREB
phosphorylation could promote ERK1/2 and cPKC-mediated
up-regulation of bcl-2 and bcl-xl, and subsequently decrease cell
apoptosis.
The family of MAPKs including ERK1/2, p38, and JNK1/2,
is largely characterized as proline-directed serine/threonine
kinases, and plays a key role in mediating proliferation,
differentiation and apoptosis caused by various stimuli
(Hamanoue et al., 2007; Han et al., 2007; Yoo et al.,
2008). Figure 5 showed that AR could promote ERK1/2
phosphorylation, which was confirmed by the result that
PD98095 blocked the protective effect of AR on OGD/R
injury-induced apoptosis. Additionally, the phosphorylation
of p90RSK, and CREB were decreased and the expression of
bcl-2, bcl-xl, and bax were significantly affected by PD98095.
Interestingly, GF109203X had the similar effect with PD98095,
suggesting that apart from ERK1/2, cPKC was also involved in
the neuroprotective mechanism of AR. cPKC including PKCα,
PKCβ1, PKCβ2, and PKCγ, are members of Protein kinase C
(PKC) and plays important roles in adjusting cell growth, death,
and stress responses (Yuspa, 1986). Furthermore, up to now, it
has been shown that there were complicated relationships and
interactions between ERK1/2 and cPKC during cell apoptosis
(Carduner et al., 2014; Darmani et al., 2015). In previously
research, Xu et al. (2013) demonstrated that simvastain provided
robust neuroprotection against dopaminergic neurodegenetation
though regulating the PI3K/Akt/caspase 3 anti-apoptotic
pathway. In our study, we examined how AR regulated ERK1/2
and cPKC anti-apoptotic mechanism unlike simvastain to play
a vital role in neuroprotective process, and finally ameliorate
ischemic stroke.
p90RSK, a high degree of sequence homology, consists of a
family of four kinases (Rsk1-4; Wallert et al., 2015). Western
blot assay (Figures 5F,G) revealed that p90RSK phosphorylation
was blocked with PD98095, whereas it was also significantly
decreased by GF109203X, demonstrating that p90RSK is a
downstream target of ERK1/2 and cPKC pathways. Furthermore,
our findings with BI-D1870 (a specific inhibitor of p90 RSK)
on decreased CREB phosphorylation notably provided further
evidence for the vital role of p90RSK in the treatment of ischemic
stroke through anti-apoptotic pathway. CREB could be activated
by phosphorylation, and regulate the expression of genes in
cellular physiological events such as apoptosis. (Hardingham
et al., 2002; Sakamoto and Frank, 2009; Kajimura et al., 2014).
According to western blot assay (Figures 6A,B), we could deduce
that CREB, a downstream target of both ERK1/2 and cPKC, was
activated by phospho-p90RSK and involved in the regulation of
apoptotic cell death.
To demonstrate how p90RSK and CREB regulate the
expressions of bcl-2, bcl-xl, and bax, we further evaluated
the phospho-p90RSK localization using western blotting.
The nuclear translocation of phospho-p90RSK was markedly
increased in cortical neurons (Figures 5H–J), indicating the
underlying mechanism of AR-induced protective effect on
ischemic stroke. It has been shown that when activated by
the nuclear phospho-p90RSK, CREB, the cAMP response
element binding protein, could bound to a DNA element
known as the CRE to activate an array of downstream
genes (Kwok et al., 1994). Furthermore, KG-501 notably
inhibited the down-regulation of bax and up-regulation
of bcl-2 and bcl-xl indeced by AR (Figures 6C–I), which
provided further evidence that AR induced p90RSK
nuclear localization and the subsequent regulation of the
downstream CREB phosphorylation and nuclear apoptotic gene
expression.
In the case of the vitro study, Figure 4 showed that AR
notably promoted both ERK1/2 and cPKC phosphorylation at
2 h after incubation, which up-regulated the phosphorylation
and nuclear localization of p90RSK at 4 h after incubation.
As a consequence of the nuclear translocation of phosphor-
p90RSK, the nucleoprotein CERB was activated and bound to
the CRE, leading to the upregulation of bcl-2 and bcl-xl and
the downregulation of bax at 8 h after incubation with AR. The
in vivo data were in line with the results observed in vitro
(Figure 7), which further established a compelling rationale to
recognize the pivotal role of AR in anti-apoptosis action. Our
data provide an additional systematic mechanism through which
reduced apoptosis was induced by AR treatment and show
ERK1/2 and cPKC act vital roles in the process of anti-apoptosis
together.
Additionally, increasing evidence indicates that the enhanced
activity of ERK1/2 or cPKC results in activation of various
signaling mechanisms like reactive oxygen species (ROS)/NO,
mitogen-activated protein kinases (MAPK), nuclear factor
kappa light chain enhancer of B cells (NF-κB), and thus
leads to regulation of oxidative stress and inflammation
(Sandireddy et al., 2014; Zhang et al., 2014). Oxidative stress
and neuroinflammation have been excessively induced after
ischemic stroke, and have been clinically described as
important causative factors on various neurodegenerative
diseases such as Parkinson’s disease (PD), Alzheimer’s
disease (AD), amyotrophic lateral sclerosis (ALS), and
multiple system atrophy (MSA) (Ben Haim et al., 2015;
Chen et al., 2015; Herrera et al., 2015; Tang and Le, 2015;
Thakur and Nehru, 2015). Furthermore, accumulating
evidence suggests that inhibition of oxidative stress and
neuroinflammation could be a new therapeutic approach
for preventing brain injury from neurodegenerative diseases
(Labandeira-Garcia et al., 2011; D’Ambrosi et al., 2014; Singh
et al., 2015; Skaper et al., 2015). Thus, further studies to
investigate the effect of AR on neurodegenerative diseases are
necessary.
In summary, our study demonstrated that AR could
protect against I/R injury by reducing apoptosis in vivo
and vitro. Moreover, AR exerted anti-apoptotic effect
through both ERK1/2 and cPKC signaling pathways.
These data revealed that AR can be developed as an
effective drug for preventing neuron death after cerebral
ischemia.
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